partner cohort b
Download
Skip this Video
Download Presentation
PARTNER Cohort B

Loading in 2 Seconds...

play fullscreen
1 / 2

PARTNER Cohort B - PowerPoint PPT Presentation


  • 123 Views
  • Uploaded on

PARTNER Cohort B. Lifetime Cost Effectiveness of TranscatheterAortic Valve Replacement Compared with Standard Care Among Inoperable Patients with Severe Aortic Stenosis: Results from the PARTNER Trial (Cohort B). Objective

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' PARTNER Cohort B ' - fabian


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
partner cohort b
PARTNER Cohort B

Lifetime Cost Effectiveness of TranscatheterAortic Valve Replacement Compared with Standard Care Among Inoperable Patients with Severe Aortic Stenosis: Results from the PARTNER Trial (Cohort B)

Objective

  • In-Trial (12 month) analysis based on observed survival, quality-of-life, health care resource use, and hospital billing data
  • Lifetime analysis based on projections of survival and quality-adjusted survival

Primary Endpoint

  • Lifetime incremental cost-effectiveness ratio ($/LYG)

Secondary Endpoint

  • Lifetime incremental costs per quality-adjusted life year gained (ICER; $/QALY)
partner cohort b1
PARTNER Cohort B

Conclusions

  • TAVR was associated with index admission costs of approximately $78,540 (including estimated physician fees)
  • Observed follow-up costs were approximately $23,372 lower per patient with TAVR versus standard care, although overall costs remained substantially higher with TAVR at 1 year, which was related to a significantly higher hospitalization rate in the TAVR group (2.5% vs 1.2%; p<0.001)
  • TAVR resulted in an estimated increase in life expectancy of approximately 1.9 years and an ICER of $50,212 per life-year gained Sensitivity analyses had a minimal impact on results
ad